<p>BALB/c wild type mice were injected with 1×10<sup>5</sup> MOPC-315.BM luc<sup>+</sup> cells via the tail vein. (<b>A</b>) 42 days after MM injection mice showed high BLI signals from hematopoietic compartments such as femur/tibia and spleen. Shown are two representative mice from ventral and dorsal view immediately before cells from BM and spleens were harvested for flow cytometry. (<b>B–D</b>) Besides BM and spleen derived MM cells, we also analysed MOPC-315.BM luc+ cells from culture. Dead cells were excluded by propidium iodide staining and MOPC cells identified as CD138<sup>+</sup>CD4<sup>+</sup> double positive cells. (<b>B</b>) α4β1 integrin positive MOPC-315.BM luc<sup>+</sup> cells were identified by flow cytometry as α4<sup>+</s...
<p>Mice were treated with SU5416 (25 mg/kg/day) or equivalent amounts of vehicle. In separate experi...
<p>(A) MHC II and MHC I surface expression was examined by flow cytometry for blood B220<sup>+</sup>...
Multiple myeloma (MM) is a B-cell malignancy, where malignant plasma cells clonally expand in the bo...
<p>(A) Analysis of bone marrow cells. Cells were stained for B220, IgM, and CD43. Percentages of pro...
<p>(A) Upper left: Flow cytometric histograms of MOPC315.BM DsRed cells (solid line) and as a contro...
<p>BALB/c wild type mice were injected with 1×10<sup>5</sup> MOPC-315.BM luc<sup>+</sup> cells via t...
<p>(A-D) Analysis of Mature (M) Transitional 1 (T1) and Transitional 2 (T2) on CD19<sup>+</sup>B220<...
<p>BALB/c wild type mice were injected with 1×10<sup>5</sup> MOPC-315.BM luc<sup>+</sup> cells via t...
<p>(<b>a</b>) BM cells were stained with PE-Cy7-conjugated anti-B220 mAb followd by Alexa 647-conjug...
<p>The immuno-phenotypic profile of BM cells harvested from tibiae and femora was characterized by f...
<p>Surface expression of CD3, CD4, CD8 and CD19 were measured by flow cytometry; the relative fluore...
a<p>Mice were treated with SU5416 (25 mg/kg/day) or equivalent amounts of vehicle. Some SU5416-treat...
Identification of the precise location, where hematopoietic stem cells (HSCs) reside in the bone mar...
<p>(<b>A–B</b>) Flow cytometry analysis of BM cells revealed decreased LT-HSCs and ST-HSCs and incre...
<p>C57BL/6 mice were challenged with E.G7 cells and then, 7 days post tumor challenge, were treated ...
<p>Mice were treated with SU5416 (25 mg/kg/day) or equivalent amounts of vehicle. In separate experi...
<p>(A) MHC II and MHC I surface expression was examined by flow cytometry for blood B220<sup>+</sup>...
Multiple myeloma (MM) is a B-cell malignancy, where malignant plasma cells clonally expand in the bo...
<p>(A) Analysis of bone marrow cells. Cells were stained for B220, IgM, and CD43. Percentages of pro...
<p>(A) Upper left: Flow cytometric histograms of MOPC315.BM DsRed cells (solid line) and as a contro...
<p>BALB/c wild type mice were injected with 1×10<sup>5</sup> MOPC-315.BM luc<sup>+</sup> cells via t...
<p>(A-D) Analysis of Mature (M) Transitional 1 (T1) and Transitional 2 (T2) on CD19<sup>+</sup>B220<...
<p>BALB/c wild type mice were injected with 1×10<sup>5</sup> MOPC-315.BM luc<sup>+</sup> cells via t...
<p>(<b>a</b>) BM cells were stained with PE-Cy7-conjugated anti-B220 mAb followd by Alexa 647-conjug...
<p>The immuno-phenotypic profile of BM cells harvested from tibiae and femora was characterized by f...
<p>Surface expression of CD3, CD4, CD8 and CD19 were measured by flow cytometry; the relative fluore...
a<p>Mice were treated with SU5416 (25 mg/kg/day) or equivalent amounts of vehicle. Some SU5416-treat...
Identification of the precise location, where hematopoietic stem cells (HSCs) reside in the bone mar...
<p>(<b>A–B</b>) Flow cytometry analysis of BM cells revealed decreased LT-HSCs and ST-HSCs and incre...
<p>C57BL/6 mice were challenged with E.G7 cells and then, 7 days post tumor challenge, were treated ...
<p>Mice were treated with SU5416 (25 mg/kg/day) or equivalent amounts of vehicle. In separate experi...
<p>(A) MHC II and MHC I surface expression was examined by flow cytometry for blood B220<sup>+</sup>...
Multiple myeloma (MM) is a B-cell malignancy, where malignant plasma cells clonally expand in the bo...